This company has been marked as potentially delisted and may not be actively trading. Tocagen (TOCA) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock TOCA vs. CAPR, PHAR, ARVN, ANAB, MRVI, URGN, TYRA, PGEN, ORIC, and OMERShould you be buying Tocagen stock or one of its competitors? The main competitors of Tocagen include Capricor Therapeutics (CAPR), Pharming Group (PHAR), Arvinas (ARVN), AnaptysBio (ANAB), Maravai LifeSciences (MRVI), UroGen Pharma (URGN), Tyra Biosciences (TYRA), Precigen (PGEN), ORIC Pharmaceuticals (ORIC), and Omeros (OMER). These companies are all part of the "medical" sector. Tocagen vs. Capricor Therapeutics Pharming Group Arvinas AnaptysBio Maravai LifeSciences UroGen Pharma Tyra Biosciences Precigen ORIC Pharmaceuticals Omeros Tocagen (NASDAQ:TOCA) and Capricor Therapeutics (NASDAQ:CAPR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, community ranking, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations. Does the MarketBeat Community believe in TOCA or CAPR? Capricor Therapeutics received 118 more outperform votes than Tocagen when rated by MarketBeat users. However, 66.03% of users gave Tocagen an outperform vote while only 63.78% of users gave Capricor Therapeutics an outperform vote. CompanyUnderperformOutperformTocagenOutperform Votes24366.03% Underperform Votes12533.97% Capricor TherapeuticsOutperform Votes36163.78% Underperform Votes20536.22% Does the media refer more to TOCA or CAPR? In the previous week, Capricor Therapeutics had 6 more articles in the media than Tocagen. MarketBeat recorded 6 mentions for Capricor Therapeutics and 0 mentions for Tocagen. Capricor Therapeutics' average media sentiment score of 0.99 beat Tocagen's score of 0.00 indicating that Capricor Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Tocagen Neutral Capricor Therapeutics Positive Which has preferable valuation and earnings, TOCA or CAPR? Capricor Therapeutics has higher revenue and earnings than Tocagen. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Tocagen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTocagen$40K4,640.29-$63.52M-$2.69-2.88Capricor Therapeutics$22.27M19.36-$22.29M-$1.20-7.90 Which has more risk and volatility, TOCA or CAPR? Tocagen has a beta of 0.01, indicating that its stock price is 99% less volatile than the S&P 500. Comparatively, Capricor Therapeutics has a beta of 4.1, indicating that its stock price is 310% more volatile than the S&P 500. Do analysts rate TOCA or CAPR? Capricor Therapeutics has a consensus target price of $34.50, indicating a potential upside of 263.92%. Given Capricor Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Capricor Therapeutics is more favorable than Tocagen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tocagen 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Capricor Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is TOCA or CAPR more profitable? Capricor Therapeutics has a net margin of -146.86% compared to Tocagen's net margin of -176,433.34%. Capricor Therapeutics' return on equity of -112.95% beat Tocagen's return on equity.Company Net Margins Return on Equity Return on Assets Tocagen-176,433.34% -327.74% -111.87% Capricor Therapeutics -146.86%-112.95%-57.00% Do insiders and institutionals hold more shares of TOCA or CAPR? 21.4% of Tocagen shares are held by institutional investors. Comparatively, 21.7% of Capricor Therapeutics shares are held by institutional investors. 10.9% of Tocagen shares are held by insiders. Comparatively, 12.0% of Capricor Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryCapricor Therapeutics beats Tocagen on 15 of the 18 factors compared between the two stocks. Remove Ads Get Tocagen News Delivered to You Automatically Sign up to receive the latest news and ratings for TOCA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TOCA vs. The Competition Export to ExcelMetricTocagenPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$185.61M$6.74B$5.54B$7.86BDividend YieldN/A2.81%5.35%4.05%P/E Ratio-3.277.1223.4418.67Price / Sales4,640.29199.59367.8787.31Price / CashN/A65.6738.1634.64Price / Book17.245.966.634.09Net Income-$63.52M$142.11M$3.20B$246.93M Tocagen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TOCATocagenN/A$7.43-4.3%N/A+996.8%$177.72M$40,000.00-3.1477Gap DownCAPRCapricor Therapeutics2.1588 of 5 stars$13.28+3.3%$34.50+159.8%+33.6%$603.84M$22.27M-12.53N/APHARPharming Group2.3245 of 5 stars$8.76-1.0%$30.00+242.7%-26.4%$595.61M$297.20M-33.67280ARVNArvinas3.6474 of 5 stars$8.61-1.6%$35.50+312.3%-82.6%$592.13M$263.40M-3.11420Short Interest ↓High Trading VolumeANABAnaptysBio2.9607 of 5 stars$18.71+9.5%$35.11+87.7%-13.7%$573.78M$91.28M-3.08100Buyback AnnouncementHigh Trading VolumeMRVIMaravai LifeSciences4.5401 of 5 stars$2.24-1.3%$8.22+266.9%-74.9%$565.66M$259.19M-1.37610Short Interest ↑High Trading VolumeURGNUroGen Pharma3.7969 of 5 stars$11.90-1.9%$38.20+221.0%-25.1%$548.52M$90.40M-3.78200Positive NewsTYRATyra Biosciences2.0189 of 5 stars$10.65-0.4%$30.50+186.4%-48.3%$538.92MN/A-6.6120Earnings ReportAnalyst ForecastAnalyst RevisionNews CoveragePGENPrecigen3.4512 of 5 stars$1.82+0.6%$7.00+284.6%+0.3%$535.16M$3.93M-3.31190Gap UpORICORIC Pharmaceuticals4.1063 of 5 stars$7.37+4.8%$18.86+155.9%-57.2%$523.47MN/A-4.0580OMEROmeros3.5899 of 5 stars$9.02-0.9%$22.50+149.4%+148.0%$522.71MN/A-3.90210Analyst ForecastNews Coverage Remove Ads Related Companies and Tools Related Companies Capricor Therapeutics Alternatives Pharming Group Alternatives Arvinas Alternatives AnaptysBio Alternatives Maravai LifeSciences Alternatives UroGen Pharma Alternatives Tyra Biosciences Alternatives Precigen Alternatives ORIC Pharmaceuticals Alternatives Omeros Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TOCA) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | SponsoredPartner with Elon Musk on Project Colossus… Before May 1stEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredOil Surge Predicted... But Are You Ready?Do you own oil and gas stocks? Or are you thinking about buying some? But it's NOT oil stocks, futures, or ...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tocagen Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Tocagen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
